Advertisement

Absorption, Distribution, Metabolism, and Elimination of Radiolabeled Xanomeline in Healthy Male Subjects

  • A. F. DeLong
  • P. L. Bonate
  • T. Gillespie
  • D. P. Henry
  • J. H. Satterwhite
Part of the Advances in Behavioral Biology book series (ABBI, volume 44)

Abstract

Collaboration between scientists at Novo Nordisk Inc. and Eli Lilly and Company has produced xanomeline, one of the most selective M1 agonists known. In vitro pharmacologic activity demonstrated and defined the unique M1 agonist specificity associated with xanomeline. An increasing amount of data suggests that the M1 receptor system may be involved in the pathophysiology of the memory defect in Alzheimer’s disease. Clinical trials to evaluate the potential of xanomeline in the treatment of patients with Alzheimer’s Disease are in progress. In order to better understand the disposition of xanomeline in humans, we gave healthy volunteers a single 75 mg 14C xanomeline dose. This study describes the analysis of radioactivity in body fluids, the characterization of parent xanomeline/metabolites, and the pharmacokinetics of xanomeline and xanomeline metabolites.

Keywords

High Performance Liquid Chromatography High Performance Liquid Chromatography Parent Drug Healthy Male Subject High Performance Liquid Chromatography Separation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer Science+Business Media New York 1995

Authors and Affiliations

  • A. F. DeLong
    • 1
  • P. L. Bonate
    • 1
  • T. Gillespie
    • 1
  • D. P. Henry
    • 2
  • J. H. Satterwhite
    • 2
  1. 1.Lilly Laboratory for Clinical ResearchEli Lilly and CompanyIndianapolisUSA
  2. 2.Department of MedicineIndiana School of MedicineIndianapolisUSA

Personalised recommendations